Oculis to Participate in Upcoming Investor Conferences

Oculis Holding AG said its management team will participate in upcoming investor conferences in April, providing updates on the company’s late-stage ophthalmic and neuro-ophthalmic pipeline.

April conference schedule

Needham Healthcare Conference
April 13-16, Virtual
Company presentation: April 14, 9:30 AM ET
Webcast link: posted on the Oculis website under the Investors & Media section when available.

Van Lanschot Kempen Life Sciences Conference
April 15-16, Amsterdam, Netherlands
Oculis management will hold one-on-one meetings.

The company said investors interested in one-on-one meetings should contact their respective representative at the sponsoring institutions to request appointments. Webcast links, when available, will be posted on the Oculis website on the Events & Presentation page.

Pipeline highlights and timing

Oculis said 2026 is a “landmark year” as it works to transform into a leader in neuro-ophthalmology and ophthalmology. Key updates cited by the company include:

• OCS-01 (DIAMOND Phase 3 trials): topline pivotal results for diabetic macular edema (DME) are on track for June 2026.
• Licaminlimab (PREDICT-1 registrational trial): being evaluated as a genotype-based development program for precision medicine in dry eye disease (DED), with topline results planned for late 2026.
• Privosegtor (PIONEER program): granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for optic neuritis (ON). Oculis said this supports its registrational program in two optic neuropathies and cited a potential $7B+ market opportunity in the U.S. alone.

Funding and expected milestones

Oculis said it has a “strong balance sheet” and “robust pipeline,” and that it is positioned to deliver six pivotal readouts with its current funding.

Company overview

Oculis is a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology. The company’s late-stage clinical pipeline includes three core product candidates:

• Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program intended to support registration plans for optic neuropathies such as optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in other neuro-ophthalmic and neurological diseases.
• OCS-01, an eye drop in pivotal registration studies aiming to become the first non-invasive topical treatment for diabetic macular edema (DME).
• Licaminlimab, a novel topical anti-TNFα in a registrational trial being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED).

Contacts

Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Forward-looking statements

The company said the press release contains forward-looking statements, including statements regarding development plans, clinical trial timing and results, regulatory and business strategy, future development plans, market opportunity, and cash runway. Oculis noted that such statements are subject to risks and uncertainties, including those described in the Risk Factors section of its annual report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Oculis said it does not undertake an obligation to update these statements except as required by law.